NCT02260648

A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia

A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 149 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib when administered in combination with atorvastatin for 12 weeks in Japanese participants with primary hypercholesterolemia.

Conditions

• Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	Evacetrapib	Administered orally
DRUG	Ezetimibe	Administered orally
DRUG	Atorvastatin	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-11-01
• Completion: 2015-11-01
• First posted: 2014-10-09
• Last updated: 2018-10-09
• Results posted: 2018-10-09

Locations

8 sites across 1 country: Japan